# AMVUTTRA

Type: Product

Source: Biotech Intelligence Brief — https://getbiobrief.com/entity/amvuttra
Canonical HTML page: https://getbiobrief.com/entity/amvuttra

## Timeline

- **2026-08-30**: Late-breaking oral presentation at ESC Congress 2026 — Alnylam presented a prespecified HELIOS-B subgroup analysis of vutrisiran according to baseline tafamidis use in 654 randomized and treated patients.
- **2026-08-30**: Simultaneous publication in Journal of the American College of Cardiology — The HELIOS-B subgroup findings were published concurrently with the ESC Congress presentation.

## Recent coverage (1 stories)

### HELIOS-B: vutrisiran benefit consistent in 259 tafamidis users
2026-08-31 00:40:39 · Sentiment: Positive · Impact: 6/10 · Sources: 3

Alnylam's HELIOS-B subgroup analysis at ESC 2026 supports RNAi-based vutrisiran as a consistent treatment across ATTR-CM patients, including 40% already on tafamidis, while zilebesiran expands the RNAi cardiovascular pipeline.
Full story: https://getbiobrief.com/story/alnylam-helios-b-vutrisiran-tafamidis-subgroup-bio

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getbiobrief.com/guides/methodology for the full editorial methodology.